Eric Surrey
No ORCID on file
· 11 papers in corpus
· active 2012-2021
Study types
- article 6
- other 2
- review 2
- rct 1
Condition tags
- endometriosis 11
- mesh:D004715 9
- dysmenorrhea 6
- mesh:D017699 5
- mesh:D004412 3
- dyspareunia 2
- infertility 1
- mesh:D004414 1
Top journals
Frequent coauthors
other
2021
OBJECTIVE: In this post hoc analysis, we evaluated the impact of elagolix on dysmenorrhea and nonmenstrual pelvic pain across menstrual period (bleeding days) and nonmenstrual (nonbleeding) days. METHODS: Data from two randomized, 6-month,…
article
2021
BACKGROUND: Elagolix is an oral, gonadotropin-releasing hormone (GnRH) receptor antagonist, that significantly reduces dysmenorrhea and non-menstrual pelvic pain (NMPP) in women with moderate to severe endometriosis-associated pain. METHODS…
article
2020
INTRODUCTION: Endometriosis symptoms are nonspecific and overlap with other gynecologic and gastrointestinal diseases, leading to long diagnostic delays. The burden of endometriosis has been documented; however, little is known about the im…
article
2020
BACKGROUND: Endometriosis is a common problem in women of reproductive age and has impacts on health-related quality of life and productivity. Fatigue is an important part of the burden of endometriosis, it is not often included as an endpo…
article
2019
ObjectiveTo estimate the impact of elagolix on work loss due to endometriosis-associated pain.DesignPost hoc analysis of data from the Elaris I and II clinical trials.SettingNot applicable.Patient(s)Employed women ages 18–49 years with mode…
review
2018
Challenges intrinsic to the accurate diagnosis of endometriosis contribute to an extended delay between the onset of symptoms and clinical confirmation. Intraoperative visualization, preferably with histologic verification, is considered by…
article
2018
OBJECTIVE: To evaluate the efficacy and safety of elagolix, an oral, nonpeptide gonadotropin-releasing hormone antagonist, over 12 months in women with endometriosis-associated pain. METHODS: Elaris Endometriosis (EM)-III and -IV were exten…
article
2018
INTRODUCTION: The prevalence of endometriosis and the need for treatment in the USA has led to the need to explore the contemporary cost burden associated with the disease. This retrospective cohort study compared direct and indirect health…
other
2017
PURPOSE: The objective of this review was to evaluate existing patient-completed screening questionnaires and/or symptom-based predictive models with respect to their potential for use as screening tools for endometriosis in adult women. Va…
rct
2017
BACKGROUND: Endometriosis is a chronic, estrogen-dependent condition that causes dysmenorrhea and pelvic pain. Elagolix, an oral, nonpeptide, gonadotropin-releasing hormone (GnRH) antagonist, produced partial to nearly full estrogen suppres…
review
2012